Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Paradigm Biopharmaceuticals Ltd. has submitted the final Phase 3 protocol for its knee osteoarthritis treatment to the US FDA, marking a significant milestone towards initiating trials in early 2025. The company has also reported a quarterly cash outflow of $4.72 million, well below its projected $7 million, and anticipates a substantial R&D rebate to support its ongoing activities. These developments position Paradigm favorably for future regulatory success and potential shareholder value creation.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
